文献速递淋巴瘤造血干细胞移植与细胞治疗

复发或难治性经典霍奇金淋巴瘤造血细胞移植的回顾性注册队列研究

Haematopoietic cell transplantation for relapsed or refractory classical Hodgkin lymphoma: a retrospective, registry-based cohort study of 19 498 patients from the EBMT Lymphoma Working Group.
PubMed 文献 · Lancet Haematol · 2026-01-01

该研究基于EBMT注册库19 498例复发或难治性经典霍奇金淋巴瘤患者,评估2010-22年首次auto-HCT或allo-HCT后结局变化。结果显示auto-HCT和allo-HCT的2年PFS与OS均随时间改善,移植时疾病状态(PR或SD/PD)负向影响PFS。

要点

  • auto-HCT后2年PFS从2010-14年63%升至2019-22年73%,OS从85%升至93%。
  • allo-HCT后2年PFS从44%升至62%,OS从66%升至72%。
  • 移植时PR或SD/PD较CR显著负向影响PFS。

核心结论

  • auto-HCT和allo-HCT后结局在2010-22年间均改善。
  • 移植时疾病状态为PR或SD/PD负向影响PFS。

研究设计与样本

  • 回顾性、基于注册库的队列研究,纳入EBMT注册的≥18岁复发或难治性经典霍奇金淋巴瘤患者。
  • 纳入2010年1月1日至2022年12月31日首次auto-HCT或首次allo-HCT,排除串联移植。
  • 最终分析19 498例:auto-HCT 15 648例,allo-HCT 3850例。

主要发现

  • auto-HCT:2年PFS从2010-14年63%(95%CI 62-65)升至2019-22年73%(71-74),OS从85%(84-86)升至93%(91-94)。
  • allo-HCT:2年PFS从2010-14年44%(95%CI 41-46)升至2019-22年62%(58-66),OS从66%(63-68)升至72%(68-75)。

临床怎么用

  • 移植时达到更佳疾病状态(非PR或SD/PD)可能改善PFS。
  • auto-HCT和allo-HCT后结局随时间改善,支持开展前瞻性试验验证。

局限性

  • 回顾性注册研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Autologous haematopoietic cell transplantation (auto-HCT) is the recommended treatment for chemosensitive relapsed Hodgkin lymphoma, while allogeneic haematopoietic cell transplantation (allo-HCT) is indicated for patients who had unsuccessful auto-HCT. The introduction of novel therapeutic agents, alongside advances in donor selection, conditioning regimens, and graft-versus-host disease prophylaxis, might improve post-transplantation outcomes, however supporting data remain limited. We aimed to evaluate changes in post-transplantation outcomes over the period 2010-22, and to identify predictors of these outcomes. METHODS: We conducted a retrospective, registry-based cohort study of patients aged 18 years or older with relapsed or refractory classical Hodgkin lymphoma undergoing first auto-HCT or first allo-HCT between Jan 1, 2010, and Dec 31, 2022, registered with the European Society for Blood and Marrow Transplantation (EBMT), with data from more than 600 transplantation centres, across 53 countries, reporting all HCTs and yearly follow-ups. Patients who received allo-HCT for relapse after auto-HCT were included but tandem transplantations were excluded. For allo-HCT, we included patients who received grafts from matched related donors, mismatched related donors, and unrelated donors. The primary endpoints were overall survival and progression-free survival, which were assessed with the Kaplan-Meier method at 2 years and 5 years after HCT. Multivariate analyses were performed using the Cox proportional-hazards regression model to identify predictive factors. FINDINGS: We identified 22 047 patients who received a first transplantation for relapsed or refractory Hodgkin lymphoma, after excluding 1324 patients with missing follow-up data and 1225 patients with nodular lymphocyte predominant Hodgkin lymphoma, 19 498 patients were retained: 15 648 received auto-HCT (6772 [43%] were female and 8839 [57%] were male, data were missing for 37 patients); median age at HCT was 35 years [IQR 27-47]; median follow-up was 2·4 years [IQR 2·3-2·5]), and 3850 received allo-HCT (1572 [41%] female and 2273 [59%] were male, data were missing for five patients; median age at HCT 32 years [IQR 26-42]; median follow-up was 3·9 years [IQR 3·8-4·1]). For auto-HCT, from years 2010-14 to years 2019-22, the 2-year progression-free survival increased from 63% (95% CI 62-65) to 73% (71-74) and overall survival increased from 85% (95% CI 84-86) to 93% (91-94). Partial response (hazard ratio [HR] 1·92 [95% CI 1·74-2·11]) or stable or progressive disease (2·45 [2·17-2·76]) at transplantation negatively affected progression-free survival. For allo-HCT, from years 2010-14 to years 2019-22, the 2-year progression-free survival, and overall survival, increased from 44% (95% CI 41-46) to 62% (58-66), and from 66% (63-68) to 72% (68-75), respectively. Partial response (HR 1·58 [95% CI 1·39-1·78]) or stable/progressive disease (2·28 [2·02-2·58]) at transplantation negatively affected progression-free survival. INTERPRETATION: To our knowledge, this is the largest study on HCT for Hodgkin lymphoma in recent years, and our findings that outcomes after auto-HCT and allo-HCT improved over time provide relevant information that could set the basis for prospective trials or additional studies. FUNDING: None.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Bazarbachi A, Fekom M, Martinez C, et al. Haematopoietic cell transplantation for relapsed or refractory classical Hodgkin lymphoma: a retrospective, registry-based cohort study of 19 498 patients from the EBMT Lymphoma Working Group. Lancet Haematol. 2026. PMID: 42532066. doi:10.1016/S2352-3026(26)00169-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。